Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
EMBO Rep ; 15(5): 540-7, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24668263

RESUMEN

A receptor-ligand interaction can evoke a broad range of biological activities in different cell types depending on receptor identity and cell type-specific post-receptor signaling intermediates. Here, we show that the TNF family member LIGHT, known to act as a death-triggering factor in motoneurons through LT-ßR, can also promote axon outgrowth and branching in motoneurons through the same receptor. LIGHT-induced axonal elongation and branching require ERK and caspase-9 pathways. This distinct response involves a compartment-specific activation of LIGHT signals, with somatic activation-inducing death, while axonal stimulation promotes axon elongation and branching in motoneurons. Following peripheral nerve damage, LIGHT increases at the lesion site through expression by invading B lymphocytes, and genetic deletion of Light significantly delays functional recovery. We propose that a central and peripheral activation of the LIGHT pathway elicits different functional responses in motoneurons.


Asunto(s)
Axones/fisiología , Neuronas Motoras/metabolismo , Miembro 14 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/genética , Miembro 14 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/metabolismo , Animales , Linfocitos B/inmunología , Butadienos/farmacología , Caspasa 9/metabolismo , Inhibidores de Caspasas/farmacología , Proliferación Celular , Quinasas MAP Reguladas por Señal Extracelular/antagonistas & inhibidores , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Flavonoides/farmacología , Receptor beta de Linfotoxina/antagonistas & inhibidores , Receptor beta de Linfotoxina/metabolismo , Ratones , Ratones Noqueados , Nitrilos/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacología , Nervio Ciático/lesiones , Nervio Ciático/patología , Miembro 14 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/biosíntesis
2.
eNeuro ; 11(5)2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38755010

RESUMEN

Cholinergic neurons of the basal forebrain represent the main source of cholinergic innervation of large parts of the neocortex and are involved in adults in the modulation of attention, memory, and arousal. During the first postnatal days, they play a crucial role in the development of cortical neurons and cortical cytoarchitecture. However, their characteristics, during this period have not been studied. To understand how they can fulfill this role, we investigated the morphological and electrophysiological maturation of cholinergic neurons of the substantia innominata-nucleus basalis of Meynert (SI/NBM) complex in the perinatal period in mice. We show that cholinergic neurons, whether or not they express gamma-aminobutyric acid (GABA) as a cotransmitter, are already functional at Embryonic Day 18. Until the end of the first postnatal week, they constitute a single population of neurons with a well developed dendritic tree, a spontaneous activity including bursting periods, and a short-latency response to depolarizations (early-firing). They are excited by both their GABAergic and glutamatergic afferents. During the second postnatal week, a second, less excitable, neuronal population emerges, with a longer delay response to depolarizations (late-firing), together with the hyperpolarizing action of GABAA receptor-mediated currents. This classification into early-firing (40%) and late-firing (60%) neurons is again independent of the coexpression of GABAergic markers. These results strongly suggest that during the first postnatal week, the specific properties of developing SI/NBM cholinergic neurons allow them to spontaneously release acetylcholine (ACh), or ACh and GABA, into the developing cortex.


Asunto(s)
Prosencéfalo Basal , Neuronas Colinérgicas , Ácido gamma-Aminobutírico , Animales , Neuronas Colinérgicas/fisiología , Neuronas Colinérgicas/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Prosencéfalo Basal/fisiología , Prosencéfalo Basal/metabolismo , Animales Recién Nacidos , Ratones Endogámicos C57BL , Femenino , Núcleo Basal de Meynert/fisiología , Núcleo Basal de Meynert/metabolismo , Sustancia Innominada/fisiología , Sustancia Innominada/metabolismo , Ratones , Receptores de GABA-A/metabolismo , Potenciales de Acción/fisiología , Técnicas de Placa-Clamp , Ácido Glutámico/metabolismo
3.
J Neurosci ; 32(14): 4901-12, 2012 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-22492046

RESUMEN

Cellular responses to protein misfolding are thought to play key roles in triggering neurodegeneration. In the mutant superoxide dismutase (mSOD1) model of amyotrophic lateral sclerosis (ALS), subsets of motoneurons are selectively vulnerable to degeneration. Fast fatigable motoneurons selectively activate an endoplasmic reticulum (ER) stress response that drives their early degeneration while a subset of mSOD1 motoneurons show exacerbated sensitivity to activation of the motoneuron-specific Fas/NO pathway. However, the links between the two mechanisms and the molecular basis of their cellular specificity remained unclear. We show that Fas activation leads, specifically in mSOD1 motoneurons, to reductions in levels of calreticulin (CRT), a calcium-binding ER chaperone. Decreased expression of CRT is both necessary and sufficient to trigger SOD1(G93A) motoneuron death through the Fas/NO pathway. In SOD1(G93A) mice in vivo, reductions in CRT precede muscle denervation and are restricted to vulnerable motor pools. In vitro, both reduced CRT and Fas activation trigger an ER stress response that is restricted to, and required for death of, vulnerable SOD1(G93A) motoneurons. Our data reveal CRT as a critical link between a motoneuron-specific death pathway and the ER stress response and point to a role of CRT levels in modulating motoneuron vulnerability to ALS.


Asunto(s)
Esclerosis Amiotrófica Lateral/metabolismo , Calreticulina/antagonistas & inhibidores , Calreticulina/metabolismo , Estrés del Retículo Endoplásmico/genética , Neuronas Motoras/metabolismo , Receptor fas/genética , Esclerosis Amiotrófica Lateral/enzimología , Esclerosis Amiotrófica Lateral/genética , Animales , Muerte Celular/genética , Supervivencia Celular/genética , Células Cultivadas , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Neuronas Motoras/enzimología , Neuronas Motoras/patología , Mutación/genética , Transducción de Señal/genética , Superóxido Dismutasa/genética
4.
J Hepatol ; 57(6): 1292-8, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22889954

RESUMEN

BACKGROUND & AIMS: Genetic studies indicate that distinct signaling modulators are each necessary but not individually sufficient for embryonic hepatocyte survival in vivo. Nevertheless, how signaling players are interconnected into functional circuits and how they coordinate the balance of cell survival and death in developing livers are still major unresolved issues. In the present study, we examined the modulation of the p53 pathway by HGF/Met in embryonic livers. METHODS: We combined pharmacological and genetic approaches to biochemically and functionally evaluate p53 pathway modulation in primary embryonic hepatocytes and in developing livers. RT-PCR arrays were applied to investigate the selectivity of p53 transcriptional response triggered by Met. RESULTS: Met recruits p53 to regulate the liver developmental program, by qualitatively modulating its transcriptional properties: turning on the Mdm2 survival gene, while keeping death and cell-cycle arrest genes Pmaip1 and p21 silent. We investigated the mechanism leading to p53 regulation by Met and found that Abl and p38MAPK are required for p53 phosphorylation on S(389), Mdm2 upregulation, and hepatocyte survival. Alteration of this signaling mechanism switches p53 properties, leading to p53-dependent cell death in embryonic livers. RT-PCR array studies affirmed the ability of the Met-Abl-p53 axis to modulate the expression of distinct genes that can be regulated by p53. CONCLUSIONS: A signaling circuit involving Abl and p38MAPK is required downstream of Met for the survival of embryonic hepatocytes, via qualitative regulation of the p53 transcriptional response, by switching its proapoptotic into survival properties.


Asunto(s)
Hepatocitos/fisiología , Hígado/embriología , Proteínas Proto-Oncogénicas c-abl/fisiología , Proteínas Proto-Oncogénicas c-met/fisiología , Transcripción Genética , Proteína p53 Supresora de Tumor/fisiología , Animales , Supervivencia Celular , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Ratones , Fosforilación , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-mdm2/genética , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
5.
J Neurochem ; 114(3): 795-809, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20477942

RESUMEN

A dominant mutation in the gene coding for the vesicle-associated membrane protein-associated protein B (VAPB) was associated with amyotrophic lateral sclerosis, a fatal paralytic disorder characterized by the selective loss of motoneurons in the brain and spinal cord. Adeno-associated viral vectors that we show to transduce up to 90% of motoneurons in vitro were used to model VAPB-associated neurodegenerative process. We observed that Adeno-associated viral-mediated over-expression of both wild-type and mutated form of human VAPB selectively induces death of primary motoneurons, albeit with different kinetics. We provide evidence that ER stress and impaired homeostatic regulation of calcium (Ca(2+)) are implicated in the death process. Finally, we found that completion of the motoneuron death program triggered by the over-expression of wild-type and mutant VAPB implicates calpains, caspase 12 and 3. Our viral-based in vitro model, which recapitulates the selective vulnerability of motoneurons to the presence of mutant VAPB and also to VAPB gene dosage effect, identifies aberrant Ca(2+) signals and ER-derived death pathways as important events in the motoneuron degenerative process.


Asunto(s)
Esclerosis Amiotrófica Lateral/metabolismo , Señalización del Calcio/fisiología , Dependovirus/genética , Retículo Endoplásmico/fisiología , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Neuronas Motoras/patología , Degeneración Nerviosa/metabolismo , Esclerosis Amiotrófica Lateral/genética , Esclerosis Amiotrófica Lateral/patología , Animales , Señalización del Calcio/genética , Muerte Celular/genética , Muerte Celular/fisiología , Células Cultivadas , Retículo Endoplásmico/patología , Humanos , Proteínas de la Membrana/fisiología , Ratones , Neuronas Motoras/metabolismo , Mutación/genética , Degeneración Nerviosa/genética , Degeneración Nerviosa/patología , Transducción Genética/métodos , Proteínas de Transporte Vesicular
6.
Neurobiol Dis ; 40(1): 222-37, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20621658

RESUMEN

Mutations in the human L1CAM gene cause neurodevelopmental disorders collectively referred to as L1 syndrome. Here, we investigated cellular pathomechanisms underlying two L1 syndrome mutations, R184Q and W1036L. We demonstrate that these mutations cause partial endoplasmic reticulum (ER) retention of L1, reduce L1 cell surface expression, but do not induce ER stress in neuronal NSC-34 cells. We provide evidence that surface trafficking of mutated L1 is affected by defective sorting to ER exit sites and attenuated ER export. However, in differentiated neuronal cultures and long-term cultured hippocampal slices, the L1-R184Q protein is restricted to cell bodies, whereas L1-W1036L also aberrantly localizes to dendrites. These trafficking defects preclude axonal targeting of L1, thereby affecting L1-mediated axon growth and arborization. Our results indicate that L1 syndrome mutations impair neuronal L1 function at different levels, firstly by attenuating ER export and secondly by interfering with polarized neuronal trafficking.


Asunto(s)
Región CA3 Hipocampal/metabolismo , Región CA3 Hipocampal/patología , Mutación/genética , Molécula L1 de Adhesión de Célula Nerviosa/genética , Neuronas/metabolismo , Neuronas/patología , Animales , Línea Celular , Membrana Celular/metabolismo , Membrana Celular/patología , Membrana Celular/ultraestructura , Polaridad Celular/genética , Retículo Endoplásmico/metabolismo , Retículo Endoplásmico/patología , Retículo Endoplásmico/ultraestructura , Humanos , Molécula L1 de Adhesión de Célula Nerviosa/fisiología , Neurogénesis/genética , Neuronas/ultraestructura , Técnicas de Cultivo de Órganos , Transporte de Proteínas/genética , Ratas , Ratas Wistar , Síndrome
7.
Mol Cell Biol ; 24(23): 10328-39, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15542841

RESUMEN

The MET tyrosine kinase, the receptor of hepatocyte growth factor-scatter factor (HGF/SF), is known to be essential for normal development and cell survival. We report that stress stimuli induce the caspase-mediated cleavage of MET in physiological cellular targets, such as epithelial cells, embryonic hepatocytes, and cortical neurons. Cleavage occurs at aspartic residue 1000 within the SVD site of the juxtamembrane region, independently of the crucial docking tyrosine residues Y1001 or Y1347 and Y1354. This cleavage generates an intracellular 40-kDa MET fragment containing the kinase domain. The p40 MET fragment itself causes apoptosis of MDCK epithelial cells and embryonic cortical neurons, whereas its kinase-dead version is impaired in proapoptotic activity. Finally, HGF/SF treatment does not favor MET cleavage and apoptosis, confirming the known survival role of ligand-activated MET. Our results show that stress stimuli convert the MET survival receptor into a proapoptotic factor.


Asunto(s)
Apoptosis , Caspasas/metabolismo , Proteínas Proto-Oncogénicas c-met/fisiología , Secuencia de Aminoácidos , Animales , Ácido Aspártico/química , Ácido Aspártico/metabolismo , Western Blotting , Caspasa 3 , Supervivencia Celular , Células Cultivadas , Citocinas/metabolismo , Perros , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Hepatocitos/metabolismo , Etiquetado Corte-Fin in Situ , Ligandos , Ratones , Microscopía Fluorescente , Datos de Secuencia Molecular , Neuronas/metabolismo , Plásmidos/metabolismo , Biosíntesis de Proteínas , Estructura Terciaria de Proteína , Proteínas Proto-Oncogénicas c-met/metabolismo , Proteínas Recombinantes/química , Transfección , Tirosina/química
8.
J Med Chem ; 49(12): 3645-52, 2006 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-16759106

RESUMEN

Several neurological disorders manifest symptoms that result from the degeneration and death of specific neurons. p53 is an important modulator of cell death, and its inhibition could be a therapeutic approach to several neuropathologies. Here, we report the design, synthesis, and biological evaluation of novel p53 inhibitors based on the imino-tetrahydrobenzothiazole scaffold. By performing studies on their mechanism of action, we find that cyclic analogue 4b and its open precursor 2b are more potent than pifithrin-alpha (PFT-alpha), which is known to block p53 pro-apoptotic activity in vitro and in vivo without acting on other pro-apoptotic pathways. Using spectroscopic methods, we also demonstrate that open form 2b is more stable than 4b in biological media. Compound 2b is converted into its corresponding active cyclic form through an intramolecular dehydration process and was found two log values more active in vivo than PFT-alpha. Thus, 2b can be considered as a new prodrug prototype that prevents in vivo p53-triggered cell death in several neuropathologies and possibly reduces cancer therapy side effects.


Asunto(s)
Benzotiazoles/síntesis química , Iminas/síntesis química , Fármacos Neuroprotectores/síntesis química , Profármacos/síntesis química , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Administración Tópica , Animales , Antineoplásicos/toxicidad , Apoptosis/efectos de los fármacos , Axotomía , Benzotiazoles/química , Benzotiazoles/farmacología , Células Cultivadas , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/biosíntesis , Diseño de Fármacos , Estabilidad de Medicamentos , Etopósido/toxicidad , Iminas/química , Iminas/farmacología , Masculino , Ratones , Neocórtex/citología , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/farmacología , Nervio Óptico/fisiología , Fosforilación , Profármacos/química , Profármacos/farmacología , Ratas , Ratas Wistar , Células Ganglionares de la Retina/citología , Células Ganglionares de la Retina/efectos de los fármacos , Tiazoles/farmacología , Tolueno/análogos & derivados , Tolueno/farmacología , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Cuerpo Vítreo
9.
Neuroreport ; 25(1): 49-54, 2014 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-24145774

RESUMEN

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by the selective and gradual loss of motoneurons in the brain and spinal cord. A persistent inflammation, typified by the activation of astrocytes and microglia, accompanies the progressive degeneration of motoneurons. Interferon gamma (IFNγ), a potent proinflammatory cytokine that is aberrantly present in the spinal cord of ALS mice and patients, has been proposed to contribute to motoneuron death by eliciting the activation of the lymphotoxin-ß receptor (LT-ßR) through its ligand LIGHT. However, the implication of IFNγ in the pathogenic process remains elusive. Here, we show that an antagonistic anti-IFNγ antibody efficiently rescues motoneurons from IFNγ-induced death. When transiently delivered in the cerebrospinal fluid through a subcutaneously implanted osmotic minipump, the neutralizing anti-IFNγ antibody significantly retarded motor function decline in a mouse model of ALS. However, this transient infusion of anti-IFNγ antibody did not increase the life expectancy of ALS mice. Our results suggest that IFNγ contributes to ALS pathogenesis and represents a potential therapeutic target for ALS.


Asunto(s)
Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Anticuerpos Neutralizantes/uso terapéutico , Interferón gamma/inmunología , Actividad Motora/efectos de los fármacos , Neuronas Motoras/efectos de los fármacos , Esclerosis Amiotrófica Lateral/inmunología , Esclerosis Amiotrófica Lateral/fisiopatología , Animales , Anticuerpos Neutralizantes/farmacología , Muerte Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Ratones , Actividad Motora/inmunología , Neuronas Motoras/inmunología
10.
PLoS One ; 6(10): e26066, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21998752

RESUMEN

Cellular homeostasis relies on a tight control of protein synthesis, folding and degradation, in which the endoplasmic reticulum (ER) quality control and the ubiquitin proteasome system (UPS) have an instrumental function. ER stress and aberrant accumulation of misfolded proteins represent a pathological signature of amyotrophic lateral sclerosis (ALS), a fatal paralytic disorder caused by the selective degeneration of motoneurons in the brain and spinal cord. Mutations in the ER-resident protein VAPB have been associated with familial forms of the disease. ALS-linked mutations cause VAPB to form cytoplasmic aggregates. We previously demonstrated that viral-mediated expression of both wildtype and mutant human VAPB (hVAPB) leads to an ER stress response that contributes to the selective death of motoneurons. However, the mechanisms behind ER stress, defective UPS and hVAPB-associated motoneuron degeneration remain elusive. Here, we show that the overexpression of wildtype and mutated hVAPB, which is found to be less stable than the wildtype protein, leads to the abnormal accumulation of ubiquitin and ubiquitin-like protein conjugates in non-human primate cells. We observed that overexpression of both forms of hVAPB elicited an ER stress response. Treatment of wildtype and mutated hVAPB expressing cells with the ER stress inhibitor salubrinal diminished the burden of ubiquitinated proteins, suggesting that ER stress contributes to the impairment of proteasome function. We also found that both wildtype and mutated hVAPB can associate with the 20S proteasome, which was found to accumulate at the ER with wildtype hVAPB or in mutant hVAPB aggregates. Our results suggest that ER stress and corruption of the proteasome function might contribute to the aberrant protein homeostasis associated with hVAPB.


Asunto(s)
Esclerosis Amiotrófica Lateral/genética , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Mutación , Complejo de la Endopetidasa Proteasomal/metabolismo , Proteínas de Transporte Vesicular/genética , Proteínas de Transporte Vesicular/metabolismo , Animales , Células COS , Chlorocebus aethiops , Retículo Endoplásmico/metabolismo , Estrés del Retículo Endoplásmico/genética , Regulación de la Expresión Génica/genética , Humanos , Proteínas Mutantes/química , Estabilidad Proteica , Transporte de Proteínas/genética , Proteolisis , Ubiquitina/metabolismo , Ubiquitinación/genética , Proteínas de Transporte Vesicular/química
11.
Development ; 134(7): 1443-51, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17329361

RESUMEN

Coordination of cell death and survival is crucial during embryogenesis and adulthood, and alteration of this balance can result in degeneration or cancer. Growth factor receptors such as Met can activate phosphatidyl-inositol-3' kinase (PI3K), a major intracellular mediator of growth and survival. PI3K can then antagonize p53-triggered cell death, but the underlying mechanisms are not fully understood. We used genetic and pharmacological approaches to uncover Met-triggered signaling pathways that regulate hepatocyte survival during embryogenesis. Here, we show that PI3K acts via mTOR (Frap1) to regulate p53 activity both in vitro and in vivo. mTOR inhibits p53 by promoting the translation of Mdm2, a negative regulator of p53. We also demonstrate that the PI3K effector Akt is required for Met-triggered Mdm2 upregulation, in addition to being necessary for the nuclear translocation of Mdm2. Inhibition of either mTOR or Mdm2 is sufficient to block cell survival induced by Hgf-Met in vitro. Moreover, in vivo inhibition of mTOR downregulates Mdm2 protein levels and induces p53-dependent apoptosis. Our studies identify a novel mechanism for Met-triggered cell survival during embryogenesis, involving translational regulation of Mdm2 by mTOR. Moreover, they reinforce mTOR as a potential drug target in cancer.


Asunto(s)
Supervivencia Celular/fisiología , Desarrollo Embrionario/fisiología , Regulación del Desarrollo de la Expresión Génica , Proteínas Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Proteínas Proto-Oncogénicas c-met/metabolismo , Transducción de Señal/fisiología , Animales , Western Blotting , Hepatocitos/citología , Hepatocitos/metabolismo , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Ratones , Ratones Transgénicos , Microscopía Fluorescente , Serina-Treonina Quinasas TOR
12.
Hepatology ; 45(5): 1210-7, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17464994

RESUMEN

The FasL-Fas couple is a general death mediator whose activated signals lead to caspase-8 activation and apoptosis in adult hepatocytes. Suppression of caspase-8 activation and cell death is a protective mechanism modulated by the FLICE-Like Inhibitory Protein (FLIP). Although hepatocyte growth factor (HGF) and its receptor Met are known to mediate cell survival in developing livers, the molecular mechanisms involved in this process are poorly understood. We show here that Met activation by HGF impairs Fas-triggered apoptosis of primary embryonic hepatocytes and cell survival correlates with inhibition of caspase-8 and caspase-3 activities. Furthermore, we found that HGF treatment prevents degradation of FLIPL triggered by Fas activation. In contrast to this, Met activation does not modulate FLIPL levels and its stability in untreated cells, thus showing the specificity of this regulatory mechanism for embryonic hepatocyte survival. Knocking down FLIP expression abolishes the ability of Met to inhibit Fas-triggered hepatocyte death, demonstrating the functional requirement of FLIP in HGF anti-apoptotic signals. By combining genetic and pharmacological approaches, we also demonstrate that the PI3K-Akt pathway is required in embryonic hepatocytes to prevent Fas-triggered FLIP degradation and death. Thus, Met acting on PI3K and Akt ensures high levels of FLIPL, and disruption of this pathway contributes to hepatic apoptosis and possibly to Fas-related liver diseases.


Asunto(s)
Proteína Reguladora de Apoptosis Similar a CASP8 y FADD/metabolismo , Hepatocitos/inmunología , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Proteínas Proto-Oncogénicas c-met/fisiología , Transducción de Señal/fisiología , Receptor fas/fisiología , Animales , Apoptosis/efectos de los fármacos , Caspasa 8/metabolismo , Supervivencia Celular , Células Cultivadas , Cromonas/farmacología , Hepatocitos/efectos de los fármacos , Ratones , Morfolinas/farmacología , Inhibidores de las Quinasa Fosfoinosítidos-3
13.
Bioorg Med Chem Lett ; 15(6): 1561-4, 2005 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-15745797

RESUMEN

Starting from various cyclic or bicyclic ketones, we have synthesized novel Pifithrin-alpha analogues bearing different methyl substituted phenyl ketone groups at the N3-position of the 2-iminothiazole heterocycle. From stability studies in a biological medium as well as under specific chemical conditions, we have shown by NMR techniques that through a dehydration process, some derivatives can generate their corresponding cyclized analogues. All of the new analogues, Pifithrin-like and polycyclic dehydrated derivatives were assessed for their p53 inactivation potency by measuring survival of cortical neurons, whose death was induced by the DNA-damaging agent etoposide. Pifithrin-alpha like 2f as well as the cyclic dehydrated 6b analogue were found to be one log more potent p53 inactivators than reference compound Pft-alpha, with EC50 values ranging around 30 nM. These results support the finding that p53 inactivation by Pft-alpha analogues could be also due to the presence of the cyclic dehydrated Pft-alpha forms, generated in situ in the biological assay incubation medium.


Asunto(s)
Tiazoles/química , Tolueno/análogos & derivados , Tolueno/química , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Animales , Benzotiazoles , Corteza Cerebral/citología , Estabilidad de Medicamentos , Etopósido/farmacología , Ratones , Modelos Químicos , Estructura Molecular , Neuronas/efectos de los fármacos , Relación Estructura-Actividad , Tiazoles/síntesis química , Tiazoles/farmacología , Tolueno/síntesis química , Tolueno/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA